Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer
Satoshi Igawa,1 Taihei Ono,1 Masashi Kasajima,1 Hideaki Manabe,1 Tomoya Fukui,1 Hisashi Mitsufuji,2 Masanori Yokoba,3 Masaru Kubota,3 Masato Katagiri,3 Jiichiro Sasaki,4 Katsuhiko Naoki1 1Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara-City, Kanagawa 252-0374,...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-06-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/impact-of-amrubicin-monotherapy-as-second-line-chemotherapy-on-outcome-peer-reviewed-article-CMAR |
| _version_ | 1818921255631323136 |
|---|---|
| author | Igawa S Ono T Kasajima M Manabe H Fukui T Mitsufuji H Yokoba M Kubota M Katagiri M Sasaki J Naoki K |
| author_facet | Igawa S Ono T Kasajima M Manabe H Fukui T Mitsufuji H Yokoba M Kubota M Katagiri M Sasaki J Naoki K |
| author_sort | Igawa S |
| collection | DOAJ |
| description | Satoshi Igawa,1 Taihei Ono,1 Masashi Kasajima,1 Hideaki Manabe,1 Tomoya Fukui,1 Hisashi Mitsufuji,2 Masanori Yokoba,3 Masaru Kubota,3 Masato Katagiri,3 Jiichiro Sasaki,4 Katsuhiko Naoki1 1Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara-City, Kanagawa 252-0374, Japan; 2Kitasato University School of Nursing, Sagamihara-City, Kanagawa 252-0329, Japan; 3School of Allied Health Sciences, Kitasato University, Sagamihara-City, Kanagawa 252-0373, Japan; 4Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara-City, Kanagawa 252-0374, JapanCorrespondence: Satoshi IgawaDepartment of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-Ku, Sagamihara-City, Kanagawa 252-0374, JapanTel +81 42 778 8506Fax +81 42 778 6412Email igawa@kitasato-u.ac.jpPurpose: Amrubicin (AMR) is an anticancer drug for patients with relapsed small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC after chemotherapy by carboplatin plus etoposide (CE) has not been sufficiently evaluated.Patients and Methods: The medical records of patients with relapsed SCLC who received AMR as second-line chemotherapy were retrospectively reviewed, and their treatment outcomes were evaluated.Results: Forty-one patients with a median age of 76 years were analyzed. The overall response rate was 26.8%. Median progression-free survival (PFS) and overall survival (OS) were 3.5 and 8.1 months, respectively. While the median PFS of 4.7 and 2.8 months in the sensitive relapse and the refractory relapse group differed significantly (P=0.043), respectively, the median OS of 10.7 and 6.8 months in the respective relapse groups did not indicate a statistically significant difference (P=0.24). The median PFS in a group with a modified Glasgow prognostic score (mGPS) of 0 and a group with a mGPS 1 or 2 were 4.5 and 1.6 months (P=0.052), respectively, and the median OS in the respective mGPS groups were 10.7 and 4.4 months (P=0.034). Multivariate analysis identified good performance status, limited disease, and mGPS 0 as favorable independent predictors of PFS and OS of AMR monotherapy. Grade 3 or higher neutropenia was observed in 23 patients (56%), and febrile neutropenia was observed in nine patients (22%). Non-hematological toxic effects were relatively mild, and pneumonitis and treatment-related deaths were not observed.Conclusion: AMR is an effective and feasible regimen for elderly patients with relapsed SCLC after CE therapy.Keywords: small-cell lung cancer, amrubicin, elderly, second-line chemotherapy, modified Glasgow prognostic score |
| first_indexed | 2024-12-20T01:34:45Z |
| format | Article |
| id | doaj.art-1cca7d0971be4b0da5da7eef4529aab6 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-20T01:34:45Z |
| publishDate | 2020-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-1cca7d0971be4b0da5da7eef4529aab62022-12-21T19:58:02ZengDove Medical PressCancer Management and Research1179-13222020-06-01Volume 124911492154769Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung CancerIgawa SOno TKasajima MManabe HFukui TMitsufuji HYokoba MKubota MKatagiri MSasaki JNaoki KSatoshi Igawa,1 Taihei Ono,1 Masashi Kasajima,1 Hideaki Manabe,1 Tomoya Fukui,1 Hisashi Mitsufuji,2 Masanori Yokoba,3 Masaru Kubota,3 Masato Katagiri,3 Jiichiro Sasaki,4 Katsuhiko Naoki1 1Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara-City, Kanagawa 252-0374, Japan; 2Kitasato University School of Nursing, Sagamihara-City, Kanagawa 252-0329, Japan; 3School of Allied Health Sciences, Kitasato University, Sagamihara-City, Kanagawa 252-0373, Japan; 4Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara-City, Kanagawa 252-0374, JapanCorrespondence: Satoshi IgawaDepartment of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-Ku, Sagamihara-City, Kanagawa 252-0374, JapanTel +81 42 778 8506Fax +81 42 778 6412Email igawa@kitasato-u.ac.jpPurpose: Amrubicin (AMR) is an anticancer drug for patients with relapsed small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC after chemotherapy by carboplatin plus etoposide (CE) has not been sufficiently evaluated.Patients and Methods: The medical records of patients with relapsed SCLC who received AMR as second-line chemotherapy were retrospectively reviewed, and their treatment outcomes were evaluated.Results: Forty-one patients with a median age of 76 years were analyzed. The overall response rate was 26.8%. Median progression-free survival (PFS) and overall survival (OS) were 3.5 and 8.1 months, respectively. While the median PFS of 4.7 and 2.8 months in the sensitive relapse and the refractory relapse group differed significantly (P=0.043), respectively, the median OS of 10.7 and 6.8 months in the respective relapse groups did not indicate a statistically significant difference (P=0.24). The median PFS in a group with a modified Glasgow prognostic score (mGPS) of 0 and a group with a mGPS 1 or 2 were 4.5 and 1.6 months (P=0.052), respectively, and the median OS in the respective mGPS groups were 10.7 and 4.4 months (P=0.034). Multivariate analysis identified good performance status, limited disease, and mGPS 0 as favorable independent predictors of PFS and OS of AMR monotherapy. Grade 3 or higher neutropenia was observed in 23 patients (56%), and febrile neutropenia was observed in nine patients (22%). Non-hematological toxic effects were relatively mild, and pneumonitis and treatment-related deaths were not observed.Conclusion: AMR is an effective and feasible regimen for elderly patients with relapsed SCLC after CE therapy.Keywords: small-cell lung cancer, amrubicin, elderly, second-line chemotherapy, modified Glasgow prognostic scorehttps://www.dovepress.com/impact-of-amrubicin-monotherapy-as-second-line-chemotherapy-on-outcome-peer-reviewed-article-CMARsmall cell lung canceramrubicinelderlysecond-line chemotherapymodified glasgow prognostic score |
| spellingShingle | Igawa S Ono T Kasajima M Manabe H Fukui T Mitsufuji H Yokoba M Kubota M Katagiri M Sasaki J Naoki K Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer Cancer Management and Research small cell lung cancer amrubicin elderly second-line chemotherapy modified glasgow prognostic score |
| title | Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer |
| title_full | Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer |
| title_fullStr | Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer |
| title_full_unstemmed | Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer |
| title_short | Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer |
| title_sort | impact of amrubicin monotherapy as second line chemotherapy on outcomes in elderly patients with relapsed extensive disease small cell lung cancer |
| topic | small cell lung cancer amrubicin elderly second-line chemotherapy modified glasgow prognostic score |
| url | https://www.dovepress.com/impact-of-amrubicin-monotherapy-as-second-line-chemotherapy-on-outcome-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT igawas impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer AT onot impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer AT kasajimam impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer AT manabeh impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer AT fukuit impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer AT mitsufujih impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer AT yokobam impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer AT kubotam impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer AT katagirim impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer AT sasakij impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer AT naokik impactofamrubicinmonotherapyassecondlinechemotherapyonoutcomesinelderlypatientswithrelapsedextensivediseasesmallcelllungcancer |